VAS
ALNY icon

Vestmark Advisory Solutions’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vestmark Advisory Solutions’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Sell
8,217
-1,372
-14% -$414K 0.02% 620
2026
Q1 		$3.17M Buy
9,589
+811
+9% +$276K 0.04% 468
2025
Q4 		$3.49M Buy
8,778
+7,693
+709% +$3.4M 0.05% 396
2025
Q3 		$495K Sell
1,085
-655
-38% -$267K 0.01% 700
2025
Q2 		$567K Buy
+1,740
New +$481K 0.01% 595

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vestmark Advisory Solutions's ALNY Position: Q2 2026 in Review

Vestmark Advisory Solutions reduced its Alnylam Pharmaceuticals (ALNY) stake by 14% in Q2 2026, selling an estimated $414K and leaving 8,217 shares worth $2.47M. The position accounts for 0.02% of the portfolio, ranked #620.

Vestmark Advisory Solutions first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.49M in Q4 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Vestmark Advisory Solutions held 8,217 shares of Alnylam Pharmaceuticals worth $2.47M as of Q2 2026.
  • Vestmark Advisory Solutions sold 1,372 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $414K.
  • Alnylam Pharmaceuticals made up 0.02% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #620 holding.
  • Vestmark Advisory Solutions first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Vestmark Advisory Solutions's Alnylam Pharmaceuticals position peaked at $3.49M in Q4 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.